259 related articles for article (PubMed ID: 36206966)
1. Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead.
Li SJ; Sun ZJ
Cancer Lett; 2022 Dec; 550():215937. PubMed ID: 36206966
[TBL] [Abstract][Full Text] [Related]
2. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials.
Hwang JK; Hong J; Yun CO
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33207653
[TBL] [Abstract][Full Text] [Related]
4. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.
Chen L; Zuo M; Zhou Q; Wang Y
Front Immunol; 2023; 14():1308890. PubMed ID: 38169820
[TBL] [Abstract][Full Text] [Related]
6. Design and application of oncolytic viruses for cancer immunotherapy.
Ylösmäki E; Cerullo V
Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L; Peng KW; Russell SJ; Diaz RM
BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option.
Ren Y; Miao JM; Wang YY; Fan Z; Kong XB; Yang L; Cheng G
Front Immunol; 2022; 13():961796. PubMed ID: 35911673
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Viruses in Cancer Treatment: A Review.
Lawler SE; Speranza MC; Cho CF; Chiocca EA
JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with oncolytic viruses and immune checkpoint inhibitors.
Chiu M; Armstrong EJL; Jennings V; Foo S; Crespo-Rodriguez E; Bozhanova G; Patin EC; McLaughlin M; Mansfield D; Baker G; Grove L; Pedersen M; Kyula J; Roulstone V; Wilkins A; McDonald F; Harrington K; Melcher A
Expert Opin Biol Ther; 2020 Jun; 20(6):635-652. PubMed ID: 32067509
[No Abstract] [Full Text] [Related]
12. The two-faces of NK cells in oncolytic virotherapy.
Marotel M; Hasim MS; Hagerman A; Ardolino M
Cytokine Growth Factor Rev; 2020 Dec; 56():59-68. PubMed ID: 32586674
[TBL] [Abstract][Full Text] [Related]
13. The emerging field of oncolytic virus-based cancer immunotherapy.
Ma R; Li Z; Chiocca EA; Caligiuri MA; Yu J
Trends Cancer; 2023 Feb; 9(2):122-139. PubMed ID: 36402738
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cells and oncolytic viruses: joining forces against cancer.
Moreno R
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33558278
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.
Feola S; Russo S; Ylösmäki E; Cerullo V
Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic Viruses and Immune Checkpoint Inhibitors: The "Hot" New Power Couple.
Lovatt C; Parker AL
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627206
[TBL] [Abstract][Full Text] [Related]
17. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.
Tian Y; Xie D; Yang L
Signal Transduct Target Ther; 2022 Apr; 7(1):117. PubMed ID: 35387984
[TBL] [Abstract][Full Text] [Related]
18. OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions.
Vazaios K; van Berkum RE; Calkoen FG; van der Lugt J; Hulleman E
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732225
[TBL] [Abstract][Full Text] [Related]
19. The Role of Oncolytic Viruses in the Treatment of Melanoma.
Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors.
Porosnicu M; Quinson AM; Crossley K; Luecke S; Lauer UM
Future Oncol; 2022 Aug; 18(24):2627-2638. PubMed ID: 35699077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
